Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

Trial Details

NCT ID

NCT05868174

Phase

PHASE1

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

89Zr-TLX250
177Lu-TLX250 and Peposertib

Locations (sample)

North Ryde, New South Wales, Australia|-33.79677,151.12436
Adelaide, Australia|-34.92866,138.59863
Brisbane, Australia|-27.46794,153.02809
Melbourne, Australia|-37.814,144.96332
Perth, Australia|-31.95224,115.8614

Key Eligibility Criteria

Histologically confirmed advanced or metastatic solid tumor that has progressed on or during/after recognized standard of care therapies and are no…
At least one measurable lesion on CT/MRI according to RECIST 1.1 with corresponding 89Zr-TLX250 uptake (i.e., CAIX positive).
CAIX positivity in at least 75% of the total lesion volume (defined as 89Zr- TLX250 uptake with intensity significantly greater than normal liver \…
ECOG status 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →